JP2016510000A - 治療用化合物およびその使用 - Google Patents

治療用化合物およびその使用 Download PDF

Info

Publication number
JP2016510000A
JP2016510000A JP2015558936A JP2015558936A JP2016510000A JP 2016510000 A JP2016510000 A JP 2016510000A JP 2015558936 A JP2015558936 A JP 2015558936A JP 2015558936 A JP2015558936 A JP 2015558936A JP 2016510000 A JP2016510000 A JP 2016510000A
Authority
JP
Japan
Prior art keywords
certain embodiments
compound
less
formula
particles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015558936A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016510000A5 (ja
Inventor
ウィンストン ザパンタ オン
ウィンストン ザパンタ オン
パヴェル ヴォイチェフ ノヴァク
パヴェル ヴォイチェフ ノヴァク
ベン シー アスキュー
ベン シー アスキュー
ジンス キム
ジンス キム
Original Assignee
カラ ファーマシューティカルズ インコーポレイテッド
カラ ファーマシューティカルズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by カラ ファーマシューティカルズ インコーポレイテッド, カラ ファーマシューティカルズ インコーポレイテッド filed Critical カラ ファーマシューティカルズ インコーポレイテッド
Publication of JP2016510000A publication Critical patent/JP2016510000A/ja
Publication of JP2016510000A5 publication Critical patent/JP2016510000A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
JP2015558936A 2013-02-20 2014-02-20 治療用化合物およびその使用 Pending JP2016510000A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361767087P 2013-02-20 2013-02-20
US61/767,087 2013-02-20
US201361898741P 2013-11-01 2013-11-01
US61/898,741 2013-11-01
PCT/US2014/017270 WO2014130612A1 (en) 2013-02-20 2014-02-20 Therapeutic compounds and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018229512A Division JP6830943B2 (ja) 2013-02-20 2018-12-07 治療用化合物および医薬組成物

Publications (2)

Publication Number Publication Date
JP2016510000A true JP2016510000A (ja) 2016-04-04
JP2016510000A5 JP2016510000A5 (ja) 2017-03-23

Family

ID=51351653

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2015558936A Pending JP2016510000A (ja) 2013-02-20 2014-02-20 治療用化合物およびその使用
JP2018229512A Expired - Fee Related JP6830943B2 (ja) 2013-02-20 2018-12-07 治療用化合物および医薬組成物
JP2020170200A Pending JP2021006574A (ja) 2013-02-20 2020-10-08 治療用化合物およびその使用
JP2022044906A Pending JP2022081661A (ja) 2013-02-20 2022-03-22 治療用化合物およびその使用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2018229512A Expired - Fee Related JP6830943B2 (ja) 2013-02-20 2018-12-07 治療用化合物および医薬組成物
JP2020170200A Pending JP2021006574A (ja) 2013-02-20 2020-10-08 治療用化合物およびその使用
JP2022044906A Pending JP2022081661A (ja) 2013-02-20 2022-03-22 治療用化合物およびその使用

Country Status (12)

Country Link
US (7) US9353123B2 (https=)
EP (2) EP3763710A1 (https=)
JP (4) JP2016510000A (https=)
KR (1) KR102277833B1 (https=)
CN (2) CN107915751A (https=)
AU (2) AU2014219024B2 (https=)
BR (1) BR112015020139A2 (https=)
CA (1) CA2900680C (https=)
ES (1) ES2831625T3 (https=)
HK (1) HK1254296A1 (https=)
MX (1) MX368903B (https=)
WO (1) WO2014130612A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019533641A (ja) * 2016-09-08 2019-11-21 カラ ファーマシューティカルズ インコーポレイテッド 治療用化合物の結晶形態およびその使用
JP2021500346A (ja) * 2017-10-20 2021-01-07 カラ ファーマシューティカルズ インコーポレイテッド Ｒｅｔ９及びｖｅｇｆｒ２阻害剤

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6669499B2 (ja) 2013-02-15 2020-03-18 カラ ファーマシューティカルズ インコーポレイテッド 治療用化合物
JP2016510000A (ja) 2013-02-20 2016-04-04 カラ ファーマシューティカルズ インコーポレイテッド 治療用化合物およびその使用
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
EP3062795A4 (en) * 2013-11-01 2017-05-31 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
NZ719185A (en) * 2013-11-01 2017-11-24 Kala Pharmaceuticals Inc Crystalline forms of therapeutic compounds and uses thereof
US9751859B2 (en) * 2015-05-04 2017-09-05 Advenchen Pharmaceuticals, LLC Process for preparing an anti-cancer agent, 1-((4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl)cyclopropanamine, its crystalline form and its salts
AU2017324713B2 (en) * 2016-09-08 2020-08-13 KALA BIO, Inc. Crystalline forms of therapeutic compounds and uses thereof
EP3509423A4 (en) 2016-09-08 2020-05-13 Kala Pharmaceuticals, Inc. CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
CN107840843A (zh) * 2017-10-17 2018-03-27 浙江工业大学义乌科学技术研究院有限公司 一种西地尼布中间体的合成方法
CN112996784B (zh) * 2018-09-18 2023-05-30 北京越之康泰生物医药科技有限公司 吲哚衍生物及其在医药上的应用
CA3167756A1 (en) * 2020-02-04 2021-08-12 Regeneron Pharmaceuticals, Inc. Treatment of ophthalmic conditions with son of sevenless 2 (sos2) inhibitors

Citations (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002527436A (ja) * 1998-10-08 2002-08-27 アストラゼネカ アクチボラグ キナゾリン誘導体
JP2002536414A (ja) * 1999-02-10 2002-10-29 アストラゼネカ アクチボラグ 血管形成阻害剤としてのキナゾリン誘導体
JP2003528917A (ja) * 2000-04-05 2003-09-30 アストラゼネカ アクチボラグ 抗高血圧薬および抗血管新生薬の治療的組合せ
JP2004525984A (ja) * 2001-04-19 2004-08-26 アストラゼネカ アクチボラグ キナゾリン誘導体
JP2005522428A (ja) * 2002-02-01 2005-07-28 アストラゼネカ アクチボラグ キナゾリン化合物
WO2005080377A1 (ja) * 2004-02-20 2005-09-01 Kirin Beer Kabushiki Kaisha TGFβ阻害活性を有する化合物およびそれを含んでなる医薬組成物
WO2005097137A2 (en) * 2004-03-31 2005-10-20 The Scripps Research Institute Advanced quinazoline based protein kinase inhibitors
JP2006515961A (ja) * 2003-01-27 2006-06-08 スリーエム イノベイティブ プロパティズ カンパニー 全内反射を利用する蛍燐光体系光源
JP2007501210A (ja) * 2003-08-06 2007-01-25 アストラゼネカ アクチボラグ 血管新生阻害剤としてのキナゾリン誘導体
JP2007518823A (ja) * 2004-01-23 2007-07-12 アムゲン インコーポレイテッド キノリン、キナゾリン、ピリジン、及びピリミジン化合物と炎症、血管新生、及び癌に対する治療におけるそれら化合物の用途
JP2008514576A (ja) * 2004-09-27 2008-05-08 アストラゼネカ アクチボラグ Ａｚｄ２１７１およびイマチニブを含む癌組合せ療法
WO2009030224A2 (de) * 2007-09-07 2009-03-12 Schebo Biotech Ag Neue chinazolin- verbindungen und ihre verwendung zur therapie von krebserkrankungen
JP2010521473A (ja) * 2007-03-14 2010-06-24 アドベンチェン ラボラトリーズ，エル エル シー 血管形成阻害剤としての化合物
JP2010539094A (ja) * 2007-09-10 2010-12-16 キュリス，インコーポレイテッド 亜鉛結合部分を含むｖｅｇｆｒインヒビター
CN102086211A (zh) * 2009-12-08 2011-06-08 深圳市东阳光实业发展有限公司 作为蛋白激酶抑制剂的芳杂环化合物
JP2011520887A (ja) * 2008-05-13 2011-07-21 アイアールエム・リミテッド・ライアビリティ・カンパニー キナーゼ阻害剤としての縮合窒素含有ヘテロ環およびその組成物
JP2012500269A (ja) * 2008-08-19 2012-01-05 チェン，グオキング，パウル，セオ キナーゼ阻害剤としての化合物
JP2012505888A (ja) * 2008-10-14 2012-03-08 クイ ニング 化合物及び使用方法
WO2012080456A1 (en) * 2010-12-17 2012-06-21 Boehringer Ingelheim International Gmbh Bicyclic ring system substituted amide functionalised phenols as medicaments
WO2012090177A2 (en) * 2010-12-30 2012-07-05 Lupin Limited Cannabinoid receptor modulators
JP2013504325A (ja) * 2009-09-09 2013-02-07 アビラ セラピューティクス， インコーポレイテッド Ｐｉ３キナーゼインヒビターおよびその使用

Family Cites Families (309)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4996335A (en) 1980-07-10 1991-02-26 Nicholas S. Bodor Soft steroids having anti-inflammatory activity
US4789724A (en) 1986-10-17 1988-12-06 Massachusetts Institute Of Technology Preparation of anhydride copolymers
CA1325382C (en) 1988-01-27 1993-12-21 Takahiro Ogawa Locally administrable therapeutic composition for inflammatory disease
US5442039A (en) 1989-07-17 1995-08-15 The Dow Chemical Company Mesogenic polycyanates and thermosets thereof
US5190956A (en) 1990-09-07 1993-03-02 Schering Corporation Certain N-substituted 3-oximino-2,4-dioxoquinolin-2,4-(1H)diones useful for treating viral infections
CZ281628B6 (cs) 1991-07-29 1996-11-13 Warner-Lambert Company Deriváty chinazolinu a farmaceutické přípravky na jejich bázi
US6235313B1 (en) 1992-04-24 2001-05-22 Brown University Research Foundation Bioadhesive microspheres and their use as drug delivery and imaging systems
US6197346B1 (en) 1992-04-24 2001-03-06 Brown Universtiy Research Foundation Bioadhesive microspheres and their use as drug delivery and imaging systems
NZ248813A (en) 1992-11-25 1995-06-27 Eastman Kodak Co Polymeric grinding media used in grinding pharmaceutical substances
GB9323290D0 (en) 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
US5364884A (en) 1993-01-21 1994-11-15 Baylor College Of Medicine Arginine compounds as ocular hypotensive agents
US5534259A (en) 1993-07-08 1996-07-09 Liposome Technology, Inc. Polymer compound and coated particle composition
EP0712421A1 (en) 1993-07-23 1996-05-22 Massachusetts Institute Of Technology Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers
US5540930A (en) 1993-10-25 1996-07-30 Pharmos Corporation Suspension of loteprednol etabonate for ear, eye, or nose treatment
DE69505949T2 (de) 1994-02-17 1999-06-02 Pankaj Hamilton Ontario Modi Arzneimittel, impfstoffe und hormone in polylaktidbeschichteten mikropartikel
WO1995024190A2 (en) 1994-03-07 1995-09-14 Sugen, Inc. Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
GB9406094D0 (en) 1994-03-28 1994-05-18 Univ Nottingham And University Polymer microspheres and a method of production thereof
US5718388A (en) 1994-05-25 1998-02-17 Eastman Kodak Continuous method of grinding pharmaceutical substances
TW384224B (en) 1994-05-25 2000-03-11 Nano Sys Llc Method of preparing submicron particles of a therapeutic or diagnostic agent
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
WO1997020578A1 (en) 1995-12-04 1997-06-12 University Of Miami Non-preserved topical corticosteroid for treatment of dry eye, filamentary keratitis, and delayed tear clearance
US6046208A (en) 1996-01-11 2000-04-04 Smithkline Beecham Corporation Substituted imidazole compounds
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
US6517860B1 (en) 1996-12-31 2003-02-11 Quadrant Holdings Cambridge, Ltd. Methods and compositions for improved bioavailability of bioactive agents for mucosal delivery
US6106819A (en) 1996-12-31 2000-08-22 Sucher; David F. Methods of treating headache and functional extraocular and intraocular myotendinitis
AU744089C (en) 1997-01-06 2003-07-31 Cerus Corporation Frangible compounds for pathogen inactivation
DE69732306T2 (de) 1997-01-16 2006-01-12 Massachusetts Institute Of Technology, Cambridge Zubereitung von partikelhaltigen arzneimitteln zur inhalation
US7301021B2 (en) 1997-07-02 2007-11-27 Smithkline Beecham Corporation Substituted imidazole compounds
GB9713980D0 (en) 1997-07-03 1997-09-10 Danbiosyst Uk New conjugates
ZA986729B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
FR2772763B1 (fr) 1997-12-24 2004-01-23 Sod Conseils Rech Applic Nouveaux analogues tetracycliques de camptothecines, leurs procedes de preparation, leur application comme medicaments et les compositions pharmaceutiques les contenant
RS49779B (sr) 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
US6165509A (en) 1998-09-01 2000-12-26 University Of Washington Pegylated drug complexed with bioadhesive polymer suitable for drug delivery and methods relating thereto
US6288082B1 (en) 1998-09-29 2001-09-11 American Cyanamid Company Substituted 3-cyanoquinolines
BR9914167B1 (pt) 1998-09-29 2011-03-09 compostos e composições farmacêuticas compreendendo 3-ciano quinolinas substituìdas.
US6372246B1 (en) 1998-12-16 2002-04-16 Ortho-Mcneil Pharmaceutical, Inc. Polyethylene glycol coating for electrostatic dry deposition of pharmaceuticals
CA2358463A1 (en) 1999-01-08 2000-07-13 Virginia Commonwealth University Polymeric delivery agents and delivery agent compounds
GB2345486A (en) 1999-01-11 2000-07-12 Glaxo Group Ltd Heteroaromatic protein tyrosine kinase inhibitors
JP2002534512A (ja) 1999-01-15 2002-10-15 ノボ ノルディスク アクティーゼルスカブ 非ペプチドｇｌｐ−１アゴニスト
JP3270834B2 (ja) 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク 抗がん剤として有用なヘテロ芳香族二環式誘導体
CA2361421A1 (en) 1999-02-03 2000-08-10 Biosante Pharmaceuticals, Inc. Therapeutic calcium phosphate particles and methods of manufacture and use
TR200102505T2 (tr) 1999-02-27 2003-01-21 Boehringer Ingelheim Pharma Kg 4-amino-kinazolin ve kinolin türevleri.
DE19911509A1 (de) 1999-03-15 2000-09-21 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US6972296B2 (en) 1999-05-07 2005-12-06 Encysive Pharmaceuticals Inc. Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
GB9910579D0 (en) 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
GB9910580D0 (en) 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
US6264981B1 (en) 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
AR035851A1 (es) 2000-03-28 2004-07-21 Wyeth Corp 3-cianoquinolinas, 3-ciano-1,6-naftiridinas y 3-ciano-1,7-naftiridinas como inhibidoras de proteina quinasas
US6521618B2 (en) 2000-03-28 2003-02-18 Wyeth 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
US6537993B2 (en) 2000-03-30 2003-03-25 Penn State Research Foundation Compounds for enhancing chemotherapy
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
WO2002012226A1 (en) 2000-08-09 2002-02-14 Astrazeneca Ab Quinoline derivatives having vegf inhibiting activity
DE10042059A1 (de) 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
CZ304344B6 (cs) 2000-09-11 2014-03-19 Novartis Vaccines & Diagnostics, Inc. Chinolinonový derivát a jeho použití a farmaceutický prostředek s obsahem tohoto derivátu
FR2814167B1 (fr) 2000-09-15 2002-11-08 Aventis Pharma Sa Preparation de la camptothecine et de ses derives
EP1332134A2 (en) 2000-10-25 2003-08-06 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
ES2382636T3 (es) 2000-10-31 2012-06-12 Surmodics Pharmaceuticals, Inc. Método para producir composiciones para la administración mejorada de moléculas bioactivas
GB0027357D0 (en) 2000-11-09 2000-12-27 Bradford Particle Design Plc Particle formation methods and their products
GB2370839A (en) 2001-01-06 2002-07-10 Benedikt Timmerman Immunogenic complex useful for disease control
US6855720B2 (en) 2001-03-01 2005-02-15 California Pacific Medical Center Nitrogen-based camptothecin derivatives
US20030125344A1 (en) 2001-03-23 2003-07-03 Bayer Corporation Rho-kinase inhibitors
WO2002088079A2 (en) 2001-05-01 2002-11-07 Bristol-Myers Squibb Company Dual inhibitors of pde 7 and pde 4
SE0101675D0 (sv) 2001-05-11 2001-05-11 Astrazeneca Ab Novel composition
DE10128110A1 (de) 2001-06-11 2003-01-02 Univ Hannover Verbindungen zum Anlagern an Nucleinsäuren
PE20030008A1 (es) 2001-06-19 2003-01-22 Bristol Myers Squibb Co Inhibidores duales de pde 7 y pde 4
EP1408971A4 (en) 2001-06-21 2006-01-25 Ariad Pharma Inc NEW QUINOLINES AND THEIR USES
WO2003000188A2 (en) 2001-06-21 2003-01-03 Ariad Pharmaceuticals, Inc. Novel quinazolines and uses thereof
JP4758607B2 (ja) 2001-06-22 2011-08-31 ジョンズ ホプキンズ ユニヴァーシティー スクール オブ メディシン 生分解性ポリマー組成物、及びその使用方法
US20050191359A1 (en) 2001-09-28 2005-09-01 Solubest Ltd. Water soluble nanoparticles and method for their production
EP1447405A4 (en) 2001-10-17 2005-01-12 Kirin Brewery CHINOLIN OR CHINAZOLINE DERIVATIVES THAT PREVENT THE AUTOPHOSPHORYLATION OF RECEPTORS FOR THE FIBROBLAST GROWTH FACTOR
GB0126433D0 (en) 2001-11-03 2002-01-02 Astrazeneca Ab Compounds
GB0128108D0 (en) 2001-11-23 2002-01-16 Astrazeneca Ab Therapeutic use
AU2002352868A1 (en) 2001-11-27 2003-06-10 Merck & Co., Inc. 4-aminoquinoline compounds
CA2468015A1 (en) 2001-11-27 2003-06-05 Merck & Co., Inc. 2-aminoquinoline compounds
WO2003048152A2 (en) 2001-12-05 2003-06-12 Tularik Inc. Inflammation modulators
EP1454898A4 (en) 2001-12-13 2006-12-13 Ajinomoto Kk NEW PHENYL ALANIDE DERIVATIVES
WO2003051906A2 (en) 2001-12-14 2003-06-26 Smithkline Beecham Corporation Compounds and methods
CA2369970A1 (en) 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor tri-peptides
US6822097B1 (en) 2002-02-07 2004-11-23 Amgen, Inc. Compounds and methods of uses
AU2006220411B2 (en) 2002-03-20 2008-06-26 Alkermes, Inc. Inhalable Sustained Therapeutic Formulations
TWI275390B (en) 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
EP1510221A4 (en) 2002-06-03 2009-04-29 Mitsubishi Tanabe Pharma Corp MEANS FOR THE PREVENTION AND / OR TREATMENT OF PERSONS EXPRESSING OR ACTIVATING HER2 AND / OR EGFR
CA2496445A1 (en) 2002-08-14 2004-02-26 Boehringer Ingelheim Pharmaceuticals, Inc. Anticoagulant and fibrinolytic therapy using p38 map kinase inhibitors
US20050256157A1 (en) 2002-08-23 2005-11-17 Chiron Corporation Combination therapy with CHK1 inhibitors
US7825132B2 (en) 2002-08-23 2010-11-02 Novartis Vaccines And Diagnostics, Inc. Inhibition of FGFR3 and treatment of multiple myeloma
CA2496164C (en) 2002-08-23 2010-11-09 Chiron Corporation Benzimidazole quinolinones and uses thereof
EP1543840A4 (en) 2002-09-26 2006-03-01 Astellas Pharma Inc AGENTS FOR IMPROVING THE ABSORPTION OF PHARMACEUTICAL PRODUCTS
WO2004044046A2 (en) 2002-11-08 2004-05-27 Encysive Pharmaceuticals Combination products with carboxylic acid derivatives that inhibit the binding of integrins to their receptors and other therapeutic compounds
US7488823B2 (en) 2003-11-10 2009-02-10 Array Biopharma, Inc. Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors
WO2004046101A2 (en) 2002-11-20 2004-06-03 Array Biopharma, Inc. Cyanoguanidines and cyanoamidines as erbb2 and egfr inhibitors
MXPA05006920A (es) 2002-12-24 2006-02-10 Astrazeneca Ab Compuestos de quinazolina.
JP2006512387A (ja) 2002-12-24 2006-04-13 アストラゼネカ アクチボラグ 化合物
ES2290529T3 (es) 2002-12-24 2008-02-16 Astrazeneca Ab Derivados de fosfonooxiquinazolina y su uso farmaceutico.
US20060167026A1 (en) 2003-01-06 2006-07-27 Hiroyuki Nawa Antipsychotic molecular-targeting epithelial growth factor receptor
US20050266090A1 (en) 2003-04-29 2005-12-01 Ales Prokop Nanoparticular targeting and therapy
WO2005044224A2 (en) 2003-05-02 2005-05-19 Case Western Reserve University Drug delivery system based on polymer nanoshells
CA2523035C (en) 2003-05-22 2011-04-26 Elan Pharma International Ltd. Sterilization of dispersions of nanoparticulate active agents with gamma radiation
JP4810427B2 (ja) 2003-05-22 2011-11-09 アボット・ラボラトリーズ インダゾール、ベンズイソオキサゾールおよびベンズイソチアゾールキナーゼ阻害剤
US7727969B2 (en) 2003-06-06 2010-06-01 Massachusetts Institute Of Technology Controlled release nanoparticle having bound oligonucleotide for targeted delivery
DE10331500A1 (de) 2003-07-11 2005-02-24 Zentaris Gmbh Neue Acridin-Derivate und deren Verwendung als Arzneimittel
US20050009809A1 (en) 2003-07-11 2005-01-13 Matthias Gerlach Acridine derivatives and their use as medicaments
WO2005030131A2 (en) 2003-09-23 2005-04-07 Replidyne, Inc Bis-quinazoline compounds for the treatment of bacterial infections
WO2005035521A1 (en) 2003-10-09 2005-04-21 Argenta Discovery Ltd. Substituted quinolines as mcr modulators
CN102225926A (zh) 2003-11-07 2011-10-26 诺华疫苗和诊断公司 具有改进药物特性的喹啉酮类化合物的药学上可接受的盐
EA009994B1 (ru) 2003-12-23 2008-06-30 Пфайзер Инк. Новые хинолиновые производные
JP4932495B2 (ja) 2004-01-23 2012-05-16 アムゲン インコーポレイテッド 化合物及び使用方法
EP1713514B1 (en) 2004-01-28 2021-11-24 Johns Hopkins University Drugs and gene carrier particles that rapidly move through mucous barriers
SE0400284D0 (sv) 2004-02-10 2004-02-10 Astrazeneca Ab Novel compounds
TW200529846A (en) 2004-02-20 2005-09-16 Wyeth Corp 3-quinolinecarbonitrile protein kinase inhibitors
US7875624B2 (en) 2004-02-20 2011-01-25 Novartis Vaccines And Diagnostics, Inc. Modulating and measuring cellular adhesion
JP2007526322A (ja) 2004-03-02 2007-09-13 マサチューセッツ インスティテュート オブ テクノロジー ナノセル薬物送達系
ATE441419T1 (de) 2004-03-25 2009-09-15 Bausch & Lomb Verwendung von loteprednoletabonat zur behanldung von trockenen augen
JP4926943B2 (ja) 2004-04-13 2012-05-09 シンタ ファーマシューティカルズ コーポレーション Ｉｌ−１２産生を阻害する二塩
US8241670B2 (en) 2004-04-15 2012-08-14 Chiasma Inc. Compositions capable of facilitating penetration across a biological barrier
ES2246694B1 (es) 2004-04-29 2007-05-01 Instituto Cientifico Y Tecnologico De Navarra, S.A. Nanoparticulas pegiladas.
AU2005237254B2 (en) 2004-05-03 2010-02-04 Novartis Ag Combinations comprising a S1P receptor agonist and a JAK3 kinase inhibitor
US20100226931A1 (en) 2004-06-24 2010-09-09 Nicholas Valiante Compounds for immunopotentiation
JP2008512350A (ja) 2004-07-01 2008-04-24 イェール ユニバーシティ 標的化され、そして高密度で薬物が負荷されるポリマー性物質
CN101031551A (zh) 2004-07-06 2007-09-05 安吉永生物制药公司 针对癌症治疗的肝细胞生长因子/c－met活性的喹唑啉调节剂
EP2364699A1 (en) 2004-09-13 2011-09-14 Eisai R&D Management Co., Ltd. Joint use of sulfonamide based compound with angiogenesis inhibitor
CA2580659C (en) 2004-09-15 2013-02-26 Ivx Animal Health, Inc. Corticosteroid having low systemic absorption
EP2452670A1 (en) 2004-10-01 2012-05-16 Ramscor, Inc. Conveniently implantable sustained release drug compositions
US20070054916A1 (en) 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
TW200616612A (en) 2004-10-08 2006-06-01 Wyeth Corp Method for the teatment of polycystic kidney disease field of invention
JP2008515961A (ja) * 2004-10-12 2008-05-15 アストラゼネカ アクチボラグ 癌に対する使用のためのキナゾリン誘導体
WO2006044660A2 (en) 2004-10-14 2006-04-27 Vanderbilt University Functionalized solid lipid nanoparticles and methods of making and using same
MX2007006230A (es) 2004-11-30 2007-07-25 Amgen Inc Quinolinas y analogos de quinazolinas y su uso como medicamentos para tratar cancer.
EP1856179B1 (en) 2004-12-10 2013-05-15 Kala Pharmaceuticals, Inc. Functionalized poly (ether-anhydride) block copolymers
MX2007010037A (es) 2005-02-18 2008-02-15 Novartis Vaccines & Diagnostic Agentes antiangiogenicos con aldesleucina.
TW200640443A (en) 2005-02-23 2006-12-01 Alcon Inc Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors
DE102005009705A1 (de) 2005-03-03 2006-09-07 Universität des Saarlandes Selektive Hemmstoffe humaner Corticoidsynthasen
WO2006092430A1 (de) 2005-03-03 2006-09-08 Universität des Saarlandes Selektive hemmstoffe humaner corticoidsynthasen
DE102005011786A1 (de) 2005-03-11 2006-09-14 Pharmasol Gmbh Verfahren zur Herstellung ultrafeiner Submicron-Suspensionen
US8048889B2 (en) 2005-03-29 2011-11-01 Xtl Biopharmaceuticals Ltd. 3,4-disubstituted coumarin and quinolone compounds
CA2603345C (en) 2005-04-01 2017-05-02 Insa Rouen New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-alzheimer agents
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
GB0509227D0 (en) 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Intracellular enzyme inhibitors
GB0509224D0 (en) 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Inhibitors of intracellular enzymatic activity
CA2607608A1 (en) 2005-05-10 2006-11-16 Alcon, Inc. Suspension formulations of nepafenac and other ophthalmic drugs for topical treatment of ophthalmic disorders
BRPI0609928A2 (pt) 2005-05-18 2010-05-11 Wyeth Corp inibidores de quinase tpl-2 de 3-cianoquinolina e métodos de fabricação e uso dos mesmos
BRPI0610147A2 (pt) 2005-05-25 2010-06-01 Wyeth Corp método para preparar e sintetizar 3-cianoquinolinas substituìdas e 4-amino-3-cianoquinolinas
CA2608394A1 (en) 2005-05-25 2006-11-30 Wyeth Methods of preparing 3-cyano-quinolines and intermediates made thereby
CN1313449C (zh) 2005-07-14 2007-05-02 沈阳中海生物技术开发有限公司 新的喹唑啉类衍生物、含有其的药物组合物以及它们的用途
EP1925941B1 (en) 2005-08-01 2012-11-28 Eisai R&D Management Co., Ltd. Method for prediction of the efficacy of vascularization inhibitor
WO2007015578A1 (ja) 2005-08-02 2007-02-08 Eisai R & D Management Co., Ltd. 血管新生阻害物質の効果を検定する方法
FR2889527A1 (fr) 2005-08-05 2007-02-09 Servier Lab Nouveaux composes analogues de la camptothecine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP4792262B2 (ja) 2005-09-09 2011-10-12 富士フイルム株式会社 有機電界発光素子及び錯体化合物
US7732613B2 (en) 2005-09-14 2010-06-08 Bristol-Myers Squibb Company Met kinase inhibitors
AU2006293410B2 (en) 2005-09-20 2012-10-04 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Nanoparticles for targeted delivery of active agents
US7875602B2 (en) 2005-10-21 2011-01-25 Sutter West Bay Hospitals Camptothecin derivatives as chemoradiosensitizing agents
CN1955183B (zh) 2005-10-28 2011-04-20 中国医学科学院药物研究所 20-位酯化的喜树碱衍生物、其制法和其药物组合物与用途
US20070149523A1 (en) 2005-11-14 2007-06-28 Jan Ehlert Thiazole Analogues and Uses Thereof
EP1785420A1 (en) 2005-11-14 2007-05-16 4Sc Ag Thiazole analogues and uses thereof
WO2007068615A2 (en) 2005-12-14 2007-06-21 F. Hoffmann-La Roche Ag Hcv prodrug formulation
US20070149480A1 (en) 2005-12-23 2007-06-28 Alcon, Inc. PHARMACEUTICAL COMPOSITION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
WO2007081978A2 (en) 2006-01-11 2007-07-19 Angion Biomedica Corporation Modulators of hepatocyte growth factor / c-met activity
US7977346B2 (en) 2006-01-17 2011-07-12 Guoqing Paul Chen Spiro compounds and methods of use
US20070196860A1 (en) 2006-01-18 2007-08-23 Invitrogen Corporation Methods for Measuring Real Time Kinase Activity
US20070178051A1 (en) 2006-01-27 2007-08-02 Elan Pharma International, Ltd. Sterilized nanoparticulate glucocorticosteroid formulations
WO2007100711A2 (en) 2006-02-24 2007-09-07 Investigen, Inc. Methods and compositions for detecting polynucleotides
GB2444101A (en) 2006-02-24 2008-05-28 Investigen Inc Methods and compositions for detecting polynucleotides
WO2007104696A1 (en) 2006-03-15 2007-09-20 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Antimalarial agents having polyaromatic structure
GB0605691D0 (en) 2006-03-21 2006-05-03 Novartis Ag Organic Compounds
KR101394768B1 (ko) 2006-03-30 2014-05-21 드라이스 파마슈티컬스 아이엔씨 캄토테신-세포 투과 펩티드 결합체 및 이를 포함하는 약학 조성물
SI2010496T1 (sl) 2006-04-14 2010-11-30 Astrazeneca Ab anilinokinolin karboksamidi kot inhibitorji CSF R kinaze
CA2651072A1 (en) 2006-05-01 2007-11-08 Pfizer Products Inc. Substituted 2-amino-fused heterocyclic compounds
JP2009537518A (ja) 2006-05-15 2009-10-29 エックスティーエル バイオファーマシューティカルズ，リミテッド ３，４−二置換クマリン及びキノロン化合物
WO2007133808A2 (en) 2006-05-15 2007-11-22 Liquidia Technologies, Inc. Nano-particles for cosmetic applications
US7691811B2 (en) 2006-05-25 2010-04-06 Bodor Nicholas S Transporter-enhanced corticosteroid activity and methods and compositions for treating dry eye
JP2009539878A (ja) 2006-06-08 2009-11-19 アレイ バイオファーマ、インコーポレイテッド キノリン化合物および使用方法
EP2044939A1 (en) 2006-06-29 2009-04-08 Eisai R&D Management Co., Ltd. Therapeutic agent for liver fibrosis
EP2037924A2 (en) 2006-07-07 2009-03-25 Steven P. Govek Bicyclic heteroaryl inhibitors of pde4
WO2008020302A2 (en) 2006-08-17 2008-02-21 Pfizer Products Inc. Heteroaromatic quinoline-based compounds as phosphodiesterase (pde) inhibitors
DE602007012559D1 (de) 2006-09-08 2011-03-31 Univ Johns Hopkins H die schleimhaut
AU2007296745B2 (en) 2006-09-11 2011-12-01 Curis, Inc. Quinazoline based EGFR inhibitors
US8821943B2 (en) 2006-09-12 2014-09-02 Board Of Regents Of The University Of Nebraska Methods and compositions for targeted delivery of therapeutic agents
US20080096193A1 (en) 2006-10-24 2008-04-24 Charles Robert Bupp Methods and compositions for detecting polynucleotides
CL2007003158A1 (es) 2006-11-02 2008-05-16 Astrazeneca Ab Procedimiento de preparacion de compuestos derivados de quinazolina o sus sales farmaceuticamente aceptables; compuestos intermediarios; procedimiento de preparacion.
TW200829555A (en) 2006-11-10 2008-07-16 Astrazeneca Ab Chemical compounds
US8414909B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
ES2392156T3 (es) 2006-12-20 2012-12-05 Amgen Inc. Heterociclos sustituidos y métodos de uso
CN100540551C (zh) 2007-02-01 2009-09-16 中国药科大学 喹啉衍生物、其制备方法及其医药用途
CN100540552C (zh) 2007-02-01 2009-09-16 中国药科大学 3-氰基喹啉衍生物、其制备方法及其医药用途
WO2008097976A1 (en) 2007-02-09 2008-08-14 Kalypsys, Inc. Heterocyclic modulators of tgr5 for treatment of disease
AU2008219166B2 (en) 2007-02-16 2013-05-16 Amgen Inc. Nitrogen-containing heterocyclyl ketones and their use as c-Met inhibitors
JP2008214323A (ja) 2007-03-08 2008-09-18 Kyowa Hakko Kogyo Co Ltd 皮膚疾患の治療及び／または予防剤
CN101679308B (zh) 2007-03-14 2014-05-07 埃克塞里艾克西斯公司 Hedgehog途径抑制剂
WO2008113161A1 (en) 2007-03-19 2008-09-25 Ulysses Pharmaceutical Products Inc. Phosphate prodrugs of quinazolinyl nitrofurans, methods of obtaining, and use of same
DE102007015169A1 (de) 2007-03-27 2008-10-02 Universität des Saarlandes Campus Saarbrücken 17Beta-Hydroxysteroid-Dehydrogenase-Typ1-Inhibitoren zur Behandlung hormonabhängiger Erkrankungen
WO2008124632A1 (en) 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Amphiphilic compound assisted nanoparticles for targeted delivery
DE102007017654A1 (de) 2007-04-12 2008-10-16 Henkel Ag & Co. Kgaa Bis(hydroxychinolin)-Metallkomplexe als Bleichkatalysatoren
CN101317847B (zh) 2007-06-06 2010-10-13 深圳市瑞谷医药技术有限公司 一种眼用或耳鼻用药物组合物及其用途
US7928111B2 (en) 2007-06-08 2011-04-19 Senomyx, Inc. Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
AR067027A1 (es) 2007-06-19 2009-09-30 Astrazeneca Ab Derivados de 2, 3-dihidro-1h-pirrol[3, 4b]quinolin-1-ona, una composicion farmaceutica que los comprende y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por la modulacion de la actividad del receptor gaba a.
WO2009014730A1 (en) 2007-07-26 2009-01-29 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
WO2009018092A1 (en) 2007-07-27 2009-02-05 The Board Of Trustees Of The Leland Stanford Junior University Supramolecular functionalization of graphitic nanoparticles for drug delivery
WO2009017838A2 (en) * 2007-08-01 2009-02-05 Exelixis, Inc. Combinations of jak-2 inhibitors and other agents
CN101108846B (zh) 2007-08-10 2011-02-09 东南大学 4-芳香氨基喹唑啉衍生物及制备方法和在制药中的应用
US20090062337A1 (en) 2007-08-31 2009-03-05 Wysis Technology Foundation, Inc. Treatment of Microbial Infections
DE102008012435A1 (de) * 2008-02-29 2009-09-03 Schebo Biotech Ag Neue Pharmazeutika, Verfahren zu ihrer Herstellung und ihre Verwendung in der Therapie
JP2010540459A (ja) 2007-09-24 2010-12-24 トラガラ ファーマシューティカルズ，インク． Ｃｏｘ‐２阻害薬及びｅｇｆｒ［ｅｒｂｂ１］とｈｅｒ‐２［ｅｒｂｂ２］の二重阻害薬を用いた癌を治療するための併用療法
ES2385118T3 (es) 2008-01-17 2012-07-18 Bayer Pharma Aktiengesellschaft Derivados de quinazolina sustituida con sulfoximina como inmunomoduladores, su preparación y uso como medicamentos
WO2009094211A1 (en) 2008-01-22 2009-07-30 Concert Pharmaceuticals Inc. Quinazoline compounds and methods of treating cancer
US8133695B2 (en) 2008-02-28 2012-03-13 Life Technologies Corporation Fluorescence polarization hERG assay
CN101239978A (zh) 2008-03-05 2008-08-13 南方医科大学 一种咪唑并吡啶类化合物
TW201000107A (en) 2008-04-09 2010-01-01 Infinity Pharmaceuticals Inc Inhibitors of fatty acid amide hydrolase
EP2288383A1 (en) 2008-05-14 2011-03-02 Amgen, Inc Combinations vegf(r) inhibitors and hepatocyte growth factor (c-met) inhibitors for the treatment of cancer
EP2149565A1 (de) 2008-07-24 2010-02-03 Bayer Schering Pharma AG Sulfonsubstituierte Chinazolinderivate als Immunmodulatoren zur Behandlung von enzündlichen und allergischen Erkrankungen
TWI580441B (zh) 2008-09-19 2017-05-01 愛爾康研究有限公司 穩定的藥學次微米懸浮液及其形成方法
CA2751761A1 (en) 2008-10-22 2010-04-29 House Ear Institute Treatment and/or prevention of inner ear conditions by modulation of a metabotropic glutamate receptor
WO2010056758A1 (en) 2008-11-12 2010-05-20 Yangbo Feng Quinazoline derivatives as kinase inhibitors
CN101747306B (zh) 2008-11-28 2012-08-29 中国中化股份有限公司 取代醚类化合物及其应用
JP5471063B2 (ja) 2009-02-23 2014-04-16 住友化学株式会社 環状化合物、その金属錯体及び変性金属錯体
TWI461197B (zh) 2009-03-12 2014-11-21 2-mercaptoquinoline-3-carboxamide as a KCNQ2 / 3 modifier
US20120022057A1 (en) 2009-03-18 2012-01-26 Schering Corporation Bicyclic compounds as inhibitors of diacyglycerol acyltransferase
US10952965B2 (en) 2009-05-15 2021-03-23 Baxter International Inc. Compositions and methods for drug delivery
US9241928B2 (en) 2009-06-26 2016-01-26 The General Hospital Corporation Antimicrobial compounds
CN102596200A (zh) 2009-11-07 2012-07-18 默克专利有限公司 作为TGF-β受体激酶抑制剂的杂芳基氨基喹啉类
EP2335686A1 (en) 2009-12-21 2011-06-22 LEK Pharmaceuticals d.d. An aqueous intravenous nanosuspension with reduced adverse effects
DE102010006121B4 (de) 2010-01-29 2022-08-11 Merck Patent Gmbh Materialien für organische Elektrolumineszenzvorrichtungen
DE102010007938A1 (de) 2010-02-12 2011-10-06 Merck Patent Gmbh Elektrolumineszierende Polymere, Verfahren zu ihrer Herstellung sowie ihre Verwendung
WO2011106168A1 (en) 2010-02-24 2011-09-01 Dcam Pharma Inc Purine compounds for treating autoimmune and demyelinating diseases
EP2538929A4 (en) 2010-02-25 2014-07-09 Univ Johns Hopkins DELAYED RELEASE OF THERAPIES IN A PART OF THE EYE
JP5654246B2 (ja) 2010-03-03 2015-01-14 一般社団法人ファルマバレープロジェクト支援機構 キナゾリン化合物を有効成分とする医薬組成物
TWI516264B (zh) 2010-05-06 2016-01-11 臺北醫學大學 芳香醯喹啉化合物
DE102010023949A1 (de) 2010-06-16 2011-12-22 F. Holzer Gmbh In-situ Lecithin-Mikroemulsionsgel-Formulierung
JP5921535B2 (ja) 2010-06-16 2016-05-24 ディナバックス テクノロジーズ コーポレイション Ｔｌｒ７および／またはｔｌｒ９阻害剤を用いる治療の方法
CA2803890A1 (en) 2010-06-25 2011-12-29 Rutgers, The State University Of New Jersey Antimicrobial agents
US20120252756A1 (en) 2010-06-25 2012-10-04 Coffey Martin J Pharmaceutical Compositions and Methods for Treating, Controlling, Ameliorating, or Reversing Conditions of the Eye
JP5826261B2 (ja) 2010-06-28 2015-12-02 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 癌に対する使用のためのキナーゼ阻害剤としての２，４−ジアリール置換［１，８］ナフチリジン
AU2011271518A1 (en) 2010-07-02 2012-12-13 Alcon Research, Ltd. Compounds for the treatment of posterior segment disorders and diseases
WO2012012627A1 (en) 2010-07-22 2012-01-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of preventing or treating viral infection
WO2012013884A1 (fr) 2010-07-29 2012-02-02 Laboratoires Fournier Sa Composes pour le traitement/la prevention des maladies inflammatoires oculaires
SG187654A1 (en) 2010-07-30 2013-03-28 Ranbaxy Lab Ltd Matrix metalloproteinase inhibitors
TW201211007A (en) 2010-08-27 2012-03-16 Gruenenthal Gmbh Substituted 2-amino-quinoline-3-carboxamides as KCNQ2/3 modulators
US10307372B2 (en) 2010-09-10 2019-06-04 The Johns Hopkins University Rapid diffusion of large polymeric nanoparticles in the mammalian brain
WO2012040499A2 (en) 2010-09-22 2012-03-29 Surface Logix, Inc. Metabolic inhibitors
MX2013003362A (es) 2010-09-24 2013-06-05 Ranbaxy Lab Ltd Inhibidores de metaloproteinasa de matriz.
AU2011306397A1 (en) 2010-09-24 2013-05-02 Ranbaxy Laboratories Limited Matrix metalloproteinase inhibitors
CA2812319A1 (en) 2010-09-24 2012-03-29 Ranbaxy Laboratories Limited Matrix metalloproteinase inhibitors
CN103347520A (zh) 2010-10-13 2013-10-09 波士顿大学管理委员会 用作癌症化学治疗的晚期sv40因子（lsf）的抑制剂
EP2629760A4 (en) 2010-10-22 2014-04-02 Bind Therapeutics Inc THERAPEUTIC NANOPARTICLES CONTAINING COPOLYMERS OF HIGH MOLECULAR WEIGHT
WO2012061703A1 (en) 2010-11-05 2012-05-10 The Johns Hopkins University Compositions and methods relating to reduced mucoadhesion
DE102010050570A1 (de) 2010-11-05 2012-05-10 F. Holzer Gmbh Zusammensetzung und Arzneimittel enthaltend ω-3-Fettsäuren sowie einen Inhibitor des NF-κB-Transkriptionsfaktors
WO2012064898A1 (en) 2010-11-09 2012-05-18 Yuan Chen Singleton inhibitors of sumoylation enzymes and methods for their use
CA2818712C (en) 2010-11-24 2020-11-10 Government Of The U.S.A. Represented By The Secretary, Dept. Of Health & Human Services Compositions and methods for treating or preventing lupus
WO2012074980A2 (en) 2010-12-01 2012-06-07 Dara Biosciences, Inc. Methods of treating or preventing autoimmune disorders and liver disorders using indane acetic acid derivatives
AR084433A1 (es) 2010-12-22 2013-05-15 Ironwood Pharmaceuticals Inc Inhibidores de la faah y composiciones farmaceuticas que los contienen
WO2012088431A1 (en) 2010-12-23 2012-06-28 Ironwood Pharmaceuticals, Inc. Faah inhibitors
WO2012093117A1 (en) 2011-01-03 2012-07-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of ocular inflammatory diseases
US8980909B2 (en) 2011-01-12 2015-03-17 Crystal Biopharmaceutical Llc HDAC inhibiting derivatives of camptothecin
WO2012106534A2 (en) 2011-02-02 2012-08-09 The Regents Of The University Of California Hiv integrase inhibitors
WO2012109363A2 (en) 2011-02-08 2012-08-16 The Johns Hopkins University Mucus penetrating gene carriers
US20120214803A1 (en) 2011-02-18 2012-08-23 Vifor (International) Ag Novel Sulfonaminoquinoline Hepcidin Antagonists
EP2678052B1 (en) 2011-02-24 2018-09-26 Emory University Jab1 blocking compositions for ossification and methods related thereto
WO2012127506A1 (en) 2011-03-22 2012-09-27 Advinus Therapeutics Limited Substituted fused tricyclic compounds, compositions and medicinal applications thereof
US10316371B2 (en) 2011-03-29 2019-06-11 Trana Discovery, Inc. Screening methods for identifying specific Staphylococcus aureus inhibitors
US8507686B2 (en) 2011-04-14 2013-08-13 Allergan, Inc. Substituted bicyclic methyl azetidines as sphingosine-1 phosphate receptors modulators
AU2012242807A1 (en) 2011-04-14 2013-11-07 Allergan, Inc. Phenyl bicyclic methyl azetidine derivatives as sphingosine-1 phosphate receptors modulators
SG194209A1 (en) 2011-04-18 2013-11-29 Allergan Inc Substituted bicyclic methyl amine derivatives as sphingosine-1-phosphate receptors modulators
AU2012249601A1 (en) 2011-04-26 2013-05-09 Genentech, Inc. Compositions and method for treating autoimmune diseases
US8835410B2 (en) 2011-05-10 2014-09-16 Bodor Laboratories, Inc. Treatment of eyelid dermatitis
KR101967938B1 (ko) 2011-05-12 2019-04-10 포어사이트 바이오쎄라퓨틱스, 인코퍼레이티드 스테로이드 또는 비-스테로이드성 소염제를 갖는 안정한 포비돈-요오드 조성물
EP2710119A4 (en) 2011-05-17 2015-02-18 Cleave Biosciences Inc COMPOSITIONS AND METHODS FOR JAMM PROTEIN INHIBITION
US20140107151A1 (en) 2011-05-17 2014-04-17 Principia Biophama Inc. Tyrosine kinase inhibitors
WO2012162698A1 (en) 2011-05-26 2012-11-29 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the treatment of immune disorders
KR20140048216A (ko) 2011-06-29 2014-04-23 오츠카 세이야쿠 가부시키가이샤 치료 화합물로서의 퀴나졸린 및 관련된 사용 방법
WO2013013614A1 (zh) 2011-07-28 2013-01-31 南京英派药业有限公司 4-(3-杂芳基芳基氨基)喹唑啉和1-(3-杂芳基芳基氨基)异喹啉作为Hedgehog通路抑制剂及其应用
JP5753027B2 (ja) 2011-08-22 2015-07-22 ユー・ディー・シー アイルランド リミテッド 有機電界発光素子、化合物、並びに該素子を用いた発光装置、表示装置及び照明装置
TW202023575A (zh) 2011-09-16 2020-07-01 美商遠景生物製藥股份有限公司 安定之普維酮—碘組成物
WO2013061269A1 (en) 2011-10-26 2013-05-02 Micro Labs Limited Combinations of loteprednol and olopatadine for the treatment of ocular allergies
TWI549679B (zh) 2011-11-03 2016-09-21 台灣微脂體股份有限公司 疏水性喜樹鹼衍生物之醫藥組合物
WO2013065029A1 (en) 2011-11-04 2013-05-10 Micro Labs Limited Fixed dose combination containing moxifloxacin and prednisolone for treatment of ocular infections
US20130116279A1 (en) 2011-11-07 2013-05-09 Kalypsys, Inc. Bicyclic heteroaryl inhibitors of pde4
US9458131B2 (en) 2011-11-08 2016-10-04 Emory University Compounds and compositions used to epigenetically transform cells and methods related thereto
CN103102342B (zh) 2011-11-14 2014-10-29 广东东阳光药业有限公司 氨基喹唑啉类衍生物及其盐和使用方法
CN103102345B (zh) 2011-11-14 2015-06-03 广东东阳光药业有限公司 氨基喹唑啉类衍生物及其盐和使用方法
TWI577671B (zh) 2011-11-14 2017-04-11 Sunshine Lake Pharma Co Ltd Aminoquinazoline derivatives and salts thereof and methods of use thereof
EP2780026B1 (en) 2011-11-15 2019-10-23 Merck Sharp & Dohme Corp. Hcv ns3 protease inhibitors
US20140329913A1 (en) 2011-12-14 2014-11-06 The Johns Hopkins University Nanoparticles with enhanced mucosal penetration or decreased inflammation
CN103183674B (zh) 2011-12-31 2017-09-12 江苏先声药业有限公司 一类稠杂环衍生物及其应用
WO2013118071A1 (en) 2012-02-09 2013-08-15 Glenmark Pharmaceuticals S.A. BICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS
WO2013120057A1 (en) 2012-02-10 2013-08-15 The Regents Of The University Of California First row metal-based catalysts for hydosilylation
CN103304572A (zh) 2012-03-09 2013-09-18 上海医药集团股份有限公司 一类3-氰基喹啉类化合物及其药用组合物和应用
WO2013158928A2 (en) 2012-04-18 2013-10-24 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
WO2013177367A2 (en) 2012-05-23 2013-11-28 The Johns Hopkins University Compounds and methods of use thereof for treating neurodegenerative disorders
CA2875348A1 (en) 2012-06-01 2013-12-05 Oxalys Pharmaceuticals Chemical suppressors of neurotoxicity in synucleinopathic diseases
WO2013188813A2 (en) 2012-06-15 2013-12-19 The Regents Of The University Of California Novel therapeutics for brain cancer
US9062026B2 (en) 2012-07-20 2015-06-23 Cleave Biosciences, Inc. Fused pyrimidines and substituted quinazolines as inhibitors of p97
CN103804292A (zh) 2012-11-05 2014-05-21 江苏唐果医药科技有限公司 Hdm2和hdmx双重抑制剂3－腈基喹啉衍生物及其制备方法与应用
US20150259649A1 (en) 2012-11-08 2015-09-17 Emory University Cellular compositions used to restore stem cell or progenitor cell function and methods related thereto
KR20150080619A (ko) 2012-11-08 2015-07-09 아지오스 파마슈티컬스 아이엔씨. 치료적 화합물 및 조성물
WO2014074926A1 (en) 2012-11-09 2014-05-15 Rutgers, The State University Of New Jersey Therapeutic hydroxyquinolones
KR102051910B1 (ko) 2012-11-30 2019-12-09 에스에프씨주식회사 중수소 치환된 유기금속 착물 및 이를 포함하는 유기 발광 소자
CN103848785B (zh) 2012-12-04 2016-07-13 上海医药集团股份有限公司 一类氘代3-氰基喹啉类化合物、其药用组合物、制备方法及其用途
KR102146232B1 (ko) 2012-12-21 2020-08-20 메르크 파텐트 게엠베하 금속 착물
JP6669499B2 (ja) * 2013-02-15 2020-03-18 カラ ファーマシューティカルズ インコーポレイテッド 治療用化合物
KR102084421B1 (ko) 2013-02-15 2020-03-05 에스에프씨주식회사 신규한 유기 화합물 및 이를 포함하는 유기 발광 소자
JP2016510000A (ja) * 2013-02-20 2016-04-04 カラ ファーマシューティカルズ インコーポレイテッド 治療用化合物およびその使用
KR102118013B1 (ko) 2013-02-22 2020-06-05 에스에프씨주식회사 신규한 유기 화합물 및 이를 포함하는 유기 발광 소자
CA2903082C (en) 2013-03-04 2021-06-22 Advanced Medical Research Institute Of Canada Quinoline sulfonyl derivatives and uses thereof
WO2014141057A2 (en) 2013-03-12 2014-09-18 Mahesh Kandula Compositions and methods for the treatment of cancer
WO2014141110A2 (en) 2013-03-14 2014-09-18 Curadev Pharma Pvt. Ltd. Aminonitriles as kynurenine pathway inhibitors
JP6464139B2 (ja) 2013-03-14 2019-02-06 コンバージーン・リミテッド・ライアビリティ・カンパニーＣｏｎｖｅｒｇｅｎｅ Ｌｌｃ ブロモドメイン含有タンパク質の阻害のための方法および組成物
AU2014233757B2 (en) 2013-03-18 2017-12-21 Genoscience Pharma Quinolines derivatives as novel anticancer agents
WO2014182954A1 (en) 2013-05-08 2014-11-13 Colorado Seminary, Which Owns And Operates The University Of Denver Antibiotic and anti-parasitic agents that modulate class ii fructose 1,6-bisphosphate aldolase
JP2016524607A (ja) 2013-05-16 2016-08-18 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ Ｈｉｖ−１インテグラーゼの薬物耐性株を阻害するための化合物
CN105636944B (zh) 2013-10-14 2019-03-01 默克专利有限公司 用于电子器件的材料

Patent Citations (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002527436A (ja) * 1998-10-08 2002-08-27 アストラゼネカ アクチボラグ キナゾリン誘導体
JP2002536414A (ja) * 1999-02-10 2002-10-29 アストラゼネカ アクチボラグ 血管形成阻害剤としてのキナゾリン誘導体
JP2003528917A (ja) * 2000-04-05 2003-09-30 アストラゼネカ アクチボラグ 抗高血圧薬および抗血管新生薬の治療的組合せ
JP2004525984A (ja) * 2001-04-19 2004-08-26 アストラゼネカ アクチボラグ キナゾリン誘導体
JP2005522428A (ja) * 2002-02-01 2005-07-28 アストラゼネカ アクチボラグ キナゾリン化合物
JP2006515961A (ja) * 2003-01-27 2006-06-08 スリーエム イノベイティブ プロパティズ カンパニー 全内反射を利用する蛍燐光体系光源
JP2007501210A (ja) * 2003-08-06 2007-01-25 アストラゼネカ アクチボラグ 血管新生阻害剤としてのキナゾリン誘導体
JP2007518823A (ja) * 2004-01-23 2007-07-12 アムゲン インコーポレイテッド キノリン、キナゾリン、ピリジン、及びピリミジン化合物と炎症、血管新生、及び癌に対する治療におけるそれら化合物の用途
WO2005080377A1 (ja) * 2004-02-20 2005-09-01 Kirin Beer Kabushiki Kaisha TGFβ阻害活性を有する化合物およびそれを含んでなる医薬組成物
WO2005097137A2 (en) * 2004-03-31 2005-10-20 The Scripps Research Institute Advanced quinazoline based protein kinase inhibitors
JP2008514576A (ja) * 2004-09-27 2008-05-08 アストラゼネカ アクチボラグ Ａｚｄ２１７１およびイマチニブを含む癌組合せ療法
JP2010521473A (ja) * 2007-03-14 2010-06-24 アドベンチェン ラボラトリーズ，エル エル シー 血管形成阻害剤としての化合物
WO2009030224A2 (de) * 2007-09-07 2009-03-12 Schebo Biotech Ag Neue chinazolin- verbindungen und ihre verwendung zur therapie von krebserkrankungen
JP2010539094A (ja) * 2007-09-10 2010-12-16 キュリス，インコーポレイテッド 亜鉛結合部分を含むｖｅｇｆｒインヒビター
JP2011520887A (ja) * 2008-05-13 2011-07-21 アイアールエム・リミテッド・ライアビリティ・カンパニー キナーゼ阻害剤としての縮合窒素含有ヘテロ環およびその組成物
JP2012500269A (ja) * 2008-08-19 2012-01-05 チェン，グオキング，パウル，セオ キナーゼ阻害剤としての化合物
JP2012505888A (ja) * 2008-10-14 2012-03-08 クイ ニング 化合物及び使用方法
JP2013504325A (ja) * 2009-09-09 2013-02-07 アビラ セラピューティクス， インコーポレイテッド Ｐｉ３キナーゼインヒビターおよびその使用
CN102086211A (zh) * 2009-12-08 2011-06-08 深圳市东阳光实业发展有限公司 作为蛋白激酶抑制剂的芳杂环化合物
WO2012080456A1 (en) * 2010-12-17 2012-06-21 Boehringer Ingelheim International Gmbh Bicyclic ring system substituted amide functionalised phenols as medicaments
WO2012090177A2 (en) * 2010-12-30 2012-07-05 Lupin Limited Cannabinoid receptor modulators

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BIOORG. MED. CHEM. LETT., vol. ２２, JPN6018004717, 2012, pages 262 - 266, ISSN: 0003738144 *
J. MED. CHEM., vol. ５１, JPN6018004718, 2008, pages 5766 - 5779, ISSN: 0003738145 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019533641A (ja) * 2016-09-08 2019-11-21 カラ ファーマシューティカルズ インコーポレイテッド 治療用化合物の結晶形態およびその使用
JP2021500346A (ja) * 2017-10-20 2021-01-07 カラ ファーマシューティカルズ インコーポレイテッド Ｒｅｔ９及びｖｅｇｆｒ２阻害剤

Also Published As

Publication number Publication date
JP2019055988A (ja) 2019-04-11
US20200323854A1 (en) 2020-10-15
US20180104246A1 (en) 2018-04-19
AU2018202312B2 (en) 2019-10-31
AU2018202312A1 (en) 2018-04-26
US20140235657A1 (en) 2014-08-21
US11369611B2 (en) 2022-06-28
HK1254296A1 (zh) 2019-07-19
MX2015010829A (es) 2015-12-03
ES2831625T3 (es) 2021-06-09
US20160235753A1 (en) 2016-08-18
JP2022081661A (ja) 2022-05-31
WO2014130612A1 (en) 2014-08-28
US10285991B2 (en) 2019-05-14
US9353123B2 (en) 2016-05-31
JP2021006574A (ja) 2021-01-21
US10758539B2 (en) 2020-09-01
US9861634B2 (en) 2018-01-09
AU2014219024B2 (en) 2018-04-05
CN105189462B (zh) 2017-11-10
MX368903B (es) 2019-10-21
KR20150119361A (ko) 2015-10-23
EP2958895A1 (en) 2015-12-30
CA2900680C (en) 2021-08-10
KR102277833B1 (ko) 2021-07-14
US20160237094A1 (en) 2016-08-18
EP2958895A4 (en) 2016-10-26
US20190216812A1 (en) 2019-07-18
CN107915751A (zh) 2018-04-17
EP2958895B1 (en) 2020-08-19
EP3763710A1 (en) 2021-01-13
BR112015020139A2 (pt) 2017-07-18
HK1217191A1 (zh) 2016-12-30
US9833453B2 (en) 2017-12-05
CN105189462A (zh) 2015-12-23
AU2014219024A1 (en) 2015-09-03
JP6830943B2 (ja) 2021-02-17
CA2900680A1 (en) 2014-08-28
US20230116686A1 (en) 2023-04-13

Similar Documents

Publication Publication Date Title
US11369611B2 (en) Therapeutic compounds and uses thereof
JP6669499B2 (ja) 治療用化合物
HK40043769A (en) Therapeutic compounds and uses thereof
HK1217191B (en) Therapeutic compounds and uses thereof

Legal Events

Date Code Title Description
RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20151019

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151218

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20151218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170215

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170215

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180131

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180213

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180511

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180713

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180719

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180807